心血管康复医学杂志
心血管康複醫學雜誌
심혈관강복의학잡지
JOURNAL OF CARDIOVASCULAR REHABILITATION MEDICINE
2015年
1期
88-91
,共4页
血小板糖蛋白GPⅡb-Ⅲa复合物%血小板聚集抑制剂%急性冠状动脉综合征
血小闆糖蛋白GPⅡb-Ⅲa複閤物%血小闆聚集抑製劑%急性冠狀動脈綜閤徵
혈소판당단백GPⅡb-Ⅲa복합물%혈소판취집억제제%급성관상동맥종합정
Platelet glycoprotein GPIIb-IIIa complex%Platelet aggregation inhibitors%Acute coronary syndrome
血小板糖蛋白 IIb/IIIa 受体拮抗剂(GPI)通过占据 GP IIb/IIIa 受体的结合位点,阻碍纤维蛋白原与其结合,进而抑制血小板聚集,是迄今最强、最具应用价值的抗血小板药物。本文综述其在 ACS 应用的安全性和有效性研究进展。
血小闆糖蛋白 IIb/IIIa 受體拮抗劑(GPI)通過佔據 GP IIb/IIIa 受體的結閤位點,阻礙纖維蛋白原與其結閤,進而抑製血小闆聚集,是迄今最彊、最具應用價值的抗血小闆藥物。本文綜述其在 ACS 應用的安全性和有效性研究進展。
혈소판당단백 IIb/IIIa 수체길항제(GPI)통과점거 GP IIb/IIIa 수체적결합위점,조애섬유단백원여기결합,진이억제혈소판취집,시흘금최강、최구응용개치적항혈소판약물。본문종술기재 ACS 응용적안전성화유효성연구진전。
Through occupying binding site of glycoprotein IIb/IIIa receptor,platelet glycoprotein IIb/IIIa inhibitor (GPI)inhibit the combination of fibrinogen and the receptor,then inhibit platelet aggregation.GPI is the most powerful anti-platelet drug and possesses application value in ACS now.This article made an overview on the newest research progress of safety and effectiveness of GPI in ACS.